{"id":921533,"date":"2025-12-19T09:37:58","date_gmt":"2025-12-19T14:37:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/insp-shareholder-notice-42-04-stock-drop-at-inspire-medical-systems-insp-triggers-securities-fraud-lawsuit-over-concealed-medicare-billing-software-failures-inspire-v-inventory-glut-3\/"},"modified":"2025-12-19T09:37:58","modified_gmt":"2025-12-19T14:37:58","slug":"insp-shareholder-notice-42-04-stock-drop-at-inspire-medical-systems-insp-triggers-securities-fraud-lawsuit-over-concealed-medicare-billing-software-failures-inspire-v-inventory-glut-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/insp-shareholder-notice-42-04-stock-drop-at-inspire-medical-systems-insp-triggers-securities-fraud-lawsuit-over-concealed-medicare-billing-software-failures-inspire-v-inventory-glut-3\/","title":{"rendered":"INSP Shareholder Notice: $42.04 Stock Drop at Inspire Medical Systems (INSP) Triggers Securities Fraud Lawsuit Over Concealed Medicare Billing Software Failures & Inspire V Inventory Glut"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

Partner Reed Kathrein Urges Investors to Contact Firm Before January 5, 2026 <\/b>Lead Plaintiff Deadline<\/p>\n

\n SAN FRANCISCO<\/span>, Dec. 19, 2025<\/span> \/PRNewswire\/ — National investor rights law firm Hagens Berman<\/b> alerts INSP investors to the pending securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP)<\/b>. The firm is urging INSP investors who suffered substantial losses to contact attorneys before the January 5, 2026, Lead Plaintiff Deadline<\/b>. The lawsuit, which is currently pending in the U.S. District Court for the District of Minnesota, alleges<\/span> that Inspire Medical and its executives misled investors by concealing critical operational failures surrounding the launch of its next-generation device, the Inspire V<\/b> for obstructive sleep apnea.<\/b><\/p>\n

\n

\n
\n \"Class
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Class Period:<\/b>\u00a0Investors who purchased Inspire Medical (INSP)<\/b> securities between August 6, 2024, and August 4, 2025<\/b>.<\/p>\n

\n Lead Plaintiff Deadline:<\/b>
\n January 5, 2026<\/b>\n <\/p>\n

\n
\n Submit Your INSP Losses Now<\/a>
\n <\/b>: If you suffered a substantial loss on your INSP<\/b> investment, you are encouraged to contact Hagens Berman Partner Reed Kathrein to discuss your legal rights:<\/p>\n

\n Visit: www.hbsslaw.com\/investor-fraud<\/span>\/insp<\/a><\/b>\u00a0Email:<\/b>INSP@hbsslaw.com<\/a><\/b>Call:<\/b>844-916-0895<\/b><\/p>\n

\n The Heart of the Inspire Medical Systems (INSP) Fraud<\/span> Allegations<\/b>\n <\/p>\n

The securities class action complaint details how Inspire Medical allegedly<\/span> assured investors of its “operational readiness” for the Inspire V launch, claiming it was ready “to throw the switch” for full commercial rollout. These assurances, the lawsuit contends, concealed fundamental failures that made a successful launch impossible, leading to a catastrophic guidance cut and stock crash.<\/p>\n

The undisclosed operational issues that allegedly<\/span> rendered the Company’s statements materially false and misleading include:<\/p>\n

\n\n\n\n\n\n
\n

\n
\n
\n Alleged<\/span> Concealment<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n The Truth Allegedly<\/span> Revealed on Aug. 4, 2025<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Impact on Business\/Stock<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Medicare & Billing Readiness<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n The necessary software updates for Medicare claims processing<\/b> did not take effect until July 1, 2025, meaning implanting centers could not bill for procedures, stalling early adoption.<\/span>\n <\/p>\n<\/td>\n

\n

\n Delayed Inspire V rollout and bottlenecked revenue generation.<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Excess Inventory (Channel Glut)<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Customers and treatment centers held a significant surplus of the older Inspire IV device<\/b>, impacting demand for the new Inspire V product and requiring an inventory “burn down.”<\/span>\n <\/p>\n<\/td>\n

\n

\n The allegedly flawed Inspire V launch led Inspire to slash its 2025 EPS guidance by over 80%.<\/b><\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Training & Onboarding<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n “Many centers” had not completed the essential training, contracting, and onboarding required to implant the new device.<\/span>\n <\/p>\n<\/td>\n

\n

\n
\n $42.04<\/b> per share drop and 32.4%<\/b> decline in value.<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n Hagens Berman’s Investigation of the Alleged<\/span> Claims<\/b>\n <\/p>\n

“Our focus remains on the alleged<\/span> concealment of two critical points: the Medicare claims software failure<\/b> and the inventory glut<\/b> of the prior Inspire IV device,” said Reed Kathrein<\/a><\/b>, <\/b>the Hagens Berman partner leading the firm’s investigation. “The suit alleges<\/span> that Inspire’s stock collapse was the result of management allegedly<\/span> prioritizing a narrative of seamless transition over operational reality.”<\/p>\n

\n What You Can Do?:<\/b>\u00a0If you purchased Inspire Medical (INSP)<\/b> securities during the Class Period, you may have legal options. If you wish to discuss your rights or have information that may assist our investigation, please contact Hagens Berman<\/p>\n